ImaginAb, MacroGenics deal

The companies partnered to develop in vivo imaging agents for autoimmune diseases and cancer. ImaginAb will develop a clinical imaging agent based on an undisclosed MacroGenics' anti-CD3 antibody as a patient selection tool for ongoing clinical programs. ImaginAb will also engineer a CD3 binding fragment for routine clinical imaging. MacroGenics is eligible for milestones and royalties. Additionally, ImaginAb will develop imaging strategies and reagents for MacroGenics' MGA271 and for MacroGenics' cancer therapeutic programs generated with its Dual-Affinity Re-Targeting (DART) technology, which creates bifunctional antibody therapeutics. The companies could not be reached for additional details. ...